Compare Quest Diagnostics Inc (DGX) vs Gartner Inc (IT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Gartner Inc — how do they compare? Quest Diagnostics Inc trades at $202.3 (market cap $22.80B), while Gartner Inc trades at $133.83 (market cap $8.90B). The key difference: Quest Diagnostics Inc is far larger — about 2.6× Gartner Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Gartner Inc pays none. Which is the better fit depends on your goals.
| DGX | IT | |
|---|---|---|
Market Cap | $22.80B | $8.90B |
Sector | Health | Technology |
52-Week High | $216.02 | $363.58 |
52-Week Low | $166.42 | $125.68 |
Enterprise Value | $28.82B | $10.49B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Gartner (IT) trades at $141.31, up 6.06% today, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a 68.99% gross margin and 11.44% net margin, though 2025 net income declined to $729 million. Recent news highlights its leadership in AI platforms, but an ongoing legal investigation poses a near-term risk.
Outlook remains positive with a consensus price target of $157.60, suggesting 11.5% upside. Key opportunities include sustained demand for IT research and consulting, while risks involve heightened competition and the February 2025 legal probe. Institutional sentiment is mixed with 27.8% buy ratings amid cost pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →
